Oncolytics Biotech Inc ONCY

Conventional triple negative BC drug long term side effects

[Noteable]

One devastating long-term side effect from a class of chemotherapy called anthracycline is cardiotoxicity and increased risk of heart failure where the heart can’t pump enough blood to meet the body’s needs.

This is a delayed process where the heart undergoes gradual changes over time characterized by the thinning of the heart muscle and enlargement of its chambers. Unfortunately, after the onset of heart function decline, the downward cascade is irreversible, highlighting an urgent need for early prevention strategies.

https://www.biospace.com/article/releases/city-of-hope-children-s-cancer-center-children-s-oncology-group-conduct-largest-clinical-trial-seeking-to-prevent-heart-failure-among-childhood-cancer-survivors/

Although it has been 50 years from the discovery of anthracyclines, and despite recent advances in the development of targeted therapies for cancers, around 32% of breast cancer patients, 57%-70% of elderly lymphoma patients and 50–60% of childhood cancer patients are treated with anthracyclines. Some cancers benefit from neoadjuvant anthracycline-based regimes, and these include triple negative breast cancers that do not respond well to targeted therapies due to the lack of available receptors that can be targeted. [ ONCY's pelareorep + Incyte's Retifanlimab are being trialed in ONCY's Phase 2 Irene trial in metastatic Triple Negative Breast Cancer. The rationale for this clinical study is that the administration of pelareorep will prime the tumor microenvironment for enhanced tumor response to PD-1 inhibitor retifanlimab with estimate completion date of January 30, 2024.) 

https://classic.clinicaltrials.gov/ct2/show/NCT04445844

Compared to non-triple negative breast cancer patients, triple negative breast cancer patients have shown better response rate and higher pathological response rate with anthracycline use, an indicator used for predicting improved long-term outcomes.

https://oncolyticsbiotech.com/resource/irene-study-phase-2-study-of-retifanlimab-and-the-oncolytic-virus-pelareorep-in-metastatic-triple-negative-breast-cancer/

https://en.wikipedia.org/wiki/Anthracycline

[Noteable]

In 2021 Pfizer for the first time talked up its own PD-(L)1 challenger, sasanlimab.  Pfizer returned the anti-PD-L1 Bavencio to Merck KGaA in 2023, which it originally licensed in 2014. Interestingly, sasanlimab was also included in that 2014 deal: Pfizer says the molecule had been originated in house, but the two companies agreed to work together on it, before Pfizer regained

[Noteable]

 PFIZER,  INCYTE and anti-CD47 fusion proteins - June 2022 https://www.pfizer.com/news/announcements/pfizer-morphosys-and-incyte-enter-clinical-trial-collaboration-monjuvir In November 2021 Pfizer acquired Trillium Therapeutics for $2.26 Billion, the maker of two clinical-stage fusion proteins directed against CD47, the “do not eat me” signal that cancer cells co-opt to

[Noteable]

April 03, 2024 - https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=35969330